search

Active clinical trials for "Hepatitis, Chronic"

Results 711-720 of 863

Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon...

Chronic Hepatitis B

The aim of interferon therapy in HBeAg negative chronic hepatitis B was to make patients obtain immune control to hepatitis B virus defined as sustained viral response after treatment. However this target could not be get if patients keep HBV DNA positive during interferon treatment and offend relapse after treatment withdraw. In this trail, entecavir will add on patients with HBV DNA load ≥1000copies/ml after 3 months of peginterferon alpha 2a treatment, and the efficacies of the combine treatment will be evaluated by the rate of sustained viral response after 48 weeks of treatment and 24 week follow up.

Unknown status6 enrollment criteria

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Chronic Hepatitis B

As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.

Unknown status14 enrollment criteria

Steatohepatitis in Chronic Hepatitis B

Fatty LiverChronic Hepatitis b

Fatty liver disease is increasingly recognized in patients with chronic hepatitis B (CHB). Whether concurrent fatty liver disease affects the long-term outcomes of CHB is unclear. The investigators performed a longitudinal study to investigate the prognostic relevance of concurrent fatty liver disease for patients with CHB receiving antiviral therapy.

Completed4 enrollment criteria

Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC)...

Chronic Hepatitis C

Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy after 12 weeks of miravirsen monotherapy. Due to the observational nature of the study, miravirsen will not be dosed as an investigational product.

Completed2 enrollment criteria

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients...

Hepatitis C

The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective in randomized controlled clinical trials. This observational study is an effectiveness research examining the regimen of GLE/PIB, used according to local label, under real world conditions in a clinical practice patient population.

Completed4 enrollment criteria

Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy

Chronic Hepatitis C

Introduction: Vitamin D binding protein (VDBP) is a potential modulator of immune response and is associated with clinical progression of many diseases. Our aim is to assess influence of baseline 25-hydroxyvitamin D levels and VDBP single nucleotide polymorphisms (SNPs), rs4588 (C>A) and rs7041 (G>T), on baseline clinical parameters and response to interferon based therapy in chronic Hepatitis C patients in Egypt. Methodology: Genotyping will be performed by RFLP (Restriction Fragment Length Polymorphism) in treatment naïve Hepatitis C patients and healthy controls. Vitamin D levels will be assessed by ELISA. HCV RNA quantification will be performed by PCR to assess therapy outcome.

Completed2 enrollment criteria

Side Effects After Direct-acting Antiviral Treatment

Chronic Hepatitis c

The objective of this study was to assess the incidence of side effects after direct-acting antiviral therapy in patients with chronic hepatitis C virus infection.

Completed4 enrollment criteria

Quality of Life and Health Utility of Patients With CHB Infections

Chronic Hepatitis B Infection

The aim of the study is to assess the health-related quality of life (HRQOL) and preference-based health utilities of chronic hepatitis B (CHB) carriers in different stages of illness. It will also estimate the cost-effectiveness of anti-viral treatments resulting from the prevention of the progression of disease from uncomplicated CHB carriers to cirrhosis and hepatocellular carcinoma (HCC). The following hypotheses will be tested: Patients with chronic hepatitis B virus (HBV) have poorer health-related quality of life (HRQOL) than the general population; Patients with more severe stages of chronic HB infections have lower health related quality of life and health utility values; Anti-viral treatment can improve the HRQOL and health utility for patients with CHB infections; The cost-effectiveness of different treatments for chronic HBV infections can be directly compared in terms of cost/QALY gained.

Completed18 enrollment criteria

Evaluation of Liver Fibrosis With 2D-Shear Wave Elastography

Chronic Hepatitis BSonoelastography2 more

The aims of this study are to evaluate liver fibrosis with two-dimensional (2D) shear wave elastography (SWE) technique in inactive hepatitis B surface antigen (HBsAg) carriers and patients with active chronic hepatitis B (CHB), with the help of a propagation map, compare this method with histopathological results in patients with CHB and determine the suitability of 2D-SWE for use instead of liver biopsy by evaluating fibrosis before and after treatment.

Completed11 enrollment criteria

Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon...

Chronic Hepatitis C

•The purpose of this study is to compare the performance between liver biopsy and non-invasive fibrosis assessments evaluating anti-fibrotic efficacy of peginterferon plus ribavirin in patients with hepatitis C pre- and post-treatment

Completed20 enrollment criteria
1...717273...87

Need Help? Contact our team!


We'll reach out to this number within 24 hrs